Market research
7733.TSE Olympus Corporation
TSE JPY Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2T
- P/E ratio
- 35.46
- Analyst target
- 2080.7693
- Dividend yield
- 1.4%
- Beta
- 0.21
Profile
Company facts
- Exchange
- TSE
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- JP3201200007
- Market cap
- 2T
- P/E ratio
- 35.46
- Analyst target
- 2080.7693
- Dividend yield
- 1.4%
- Beta
- 0.21
About
About Olympus Corporation
Olympus Corporation, together with its subsidiaries, engages in the manufacture and sale of medical equipment in Japan, America, the Middle East, Asia, and Oceania. It operates through two segments, "Gastrointestinal Solutions and Surgical & Interventional Solutions. The company offers gastrointestinal Solutions products offer gastrointestinal endoscopes, gastroenterology devices, and medical services. The Surgical & Interventional Solutions provides urology, respiratory, surgical endoscopes, energy devices, ENT products, and gynecology products. It also provides respiratory products comprising bronchoscopy systems and devices, lung cancer products, and chronic obstructive pulmonary disease products; urology products consisting of visualization, stone management, benign prostatic hyperplasia (BPH), and BPH + bladder cancer products; surgical products, such as surgical endoscopy systems, advanced energy devices, surgical microscope, integrated procedure room solutions, and rhino-laryngoscopy systems, as well as surgical devices for the ears, nose, and throat. The company was formerly known as Olympus Optical Co., Ltd. and changed its name to Olympus Corporation in October 2003. Olympus Corporation was incorporated in 1919 and is headquartered in Hachioji, Japan.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 7733.TSE discussion.
5 years, 5 months ago
Olympus Corporation is currently in a long term downtrend where the price is trading 1.2% below its 200 day moving average.
From a valuation standpoint, the stock is 94.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.8.
Olympus Corporation's total revenue sank by 4.3% to $197B since the same quarter in the previous year.
Its net income has increased by 5.4% to $24B since the same quarter in the previous year.
Finally, its free cash flow grew by 78.1% to $42B since the same quarter in the previous year.
Based on the above factors, Olympus Corporation gets an overall score of 3/5.